Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate Bucillamine as a Potential Treatment for long COVID-19

Next Previous
Trial Profile

A Phase 2 Study to Evaluate Bucillamine as a Potential Treatment for long COVID-19

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bucillamine (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 27 Mar 2024 According to a Revive Therapeutics media release, the company has submitted a Type C meeting request package to the U.S. Food & Drug Administration for the evaluation of a proposed clinical study of Bucillamine; Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.
    • 19 Mar 2024 According to a Revive Therapeutics media release, the FDA has advised the Company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The Company expects to submit the Type C meeting request by next week.
    • 08 Apr 2020 According to a Revive Therapeutics media release, company has retained Novotech to serve as the Company CRO to pursue future human clinical studies for Bucillamine in the treatment of infectious diseases, including the coronavirus disease (COVID-19) in Asia-Pacific Countries.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top